Johannah Valentine1, Viswanath Reddy Belum2, Juanita Duran3, Kathryn Ciccolini2, Katja Schindler4, Shenhong Wu5, Mario E Lacouture6. 1. Department of Dermatology, Naval Medical Center San Diego, San Diego, California. 2. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Dermatology, Universidad del Rosario, Bogota, Colombia. 4. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Medical University of Vienna, Vienna, Austria. 5. Division of Hematology and Oncology, Stony Brook University Cancer Center, Stony Brook, New York; Division of Hematology and Oncology, Department of Medicine, Northport Veterans Affairs Medical Center, Northport, New York. 6. Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: lacoutum@mskcc.org.
Abstract
BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. RESULTS: The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001). LIMITATIONS: The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. CONCLUSION: Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment. Published by Elsevier Inc.
BACKGROUND: Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained. OBJECTIVE: We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs. METHODS: The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models. RESULTS: The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001). LIMITATIONS: The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions. CONCLUSION:Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment. Published by Elsevier Inc.
Authors: Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2017-09-14 Impact factor: 11.527
Authors: Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches Journal: An Bras Dermatol Date: 2020-02-15 Impact factor: 1.896
Authors: J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover Journal: Invest New Drugs Date: 2021-01-03 Impact factor: 3.651
Authors: Bernd Tischer; Martina Bilang; Matthias Kraemer; Philippe Ronga; Mario E Lacouture Journal: Support Care Cancer Date: 2017-11-07 Impact factor: 3.603
Authors: Mario E Lacouture; Vincent Sibaud; Milan J Anadkat; Benjamin Kaffenberger; Jonathan Leventhal; Kathleen Guindon; Ghassan Abou-Alfa Journal: Oncologist Date: 2020-10-28 Impact factor: 5.837